Management of Acute Delirium in Parkinson's Disease Patients

Introduction to Haloperidol Contraindication

The American College of Physicians and other guideline societies recommend avoiding haloperidol in patients with Parkinson's disease due to severe risk of extrapyramidal symptoms and potential neuroleptic malignant-like syndrome, with alternative agents such as quetiapine preferred 1

Quetiapine offers benefit in managing delirium symptoms with significantly lower risk of extrapyramidal symptoms compared to first-generation antipsychotics like haloperidol, and should be started at low doses (12.5-25 mg) and titrated cautiously in elderly patients 1, 2
Other atypical antipsychotics such as olanzapine or aripiprazol may also be considered, as they have less likelihood of causing extrapyramidal symptoms 2

Before administering any antipsychotic, address reversible causes of delirium by evaluating and correcting hypoxia, urinary retention, constipation, and metabolic disturbances first, and review all medications for anticholinergic burden and drug interactions that may worsen delirium 1
Non-pharmacologic interventions including family presence, reorientation, and minimizing restraints should be maximized, and benzodiazepines (lorazepam 0.5-1 mg) may be considered for acute agitation management if immediate sedation is required for safety 3, 4, 5

Recent ICU guidelines suggest NOT routinely using haloperidol or atypical antipsychotics for delirium treatment due to lack of proven efficacy and uncertain safety profile, although the Parkinson's disease population represents a specific contraindication that supersedes general ICU recommendations 1, 6
No adequately powered randomized controlled trials have established efficacy or safety of any antipsychotic for delirium in ICU patients, highlighting the need for further research in this area 7, 8